Agenus Inc. share price logo

Agenus Inc.

NASDAQ: AGEN

Small Cap

$3.00

+0.04

(+1.35%)

as on

Agenus Inc. Stock Performance

as on June 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $2.91
    $3.10
    downward going graph

    3.00%

    Downside

    3.33%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.71
    $7.34
    downward going graph

    9.67%

    Downside

    144.67%

    Upside

    downward going graph

Agenus Inc. share price movements today

Previous Close
$2.96
Open
$3.00
Volume
454.3K
Day's Low - High
$2.91 - $3.10
52 Week Low - High
$2.71 - $7.34

Agenus Inc. Historical Returns

1 Month Return
-2.91 %
3 Month Return
-21.26 %
1 Year Return
-32.89 %
3 Year Return
-91.53 %
5 Year Return
-97.15 %

Agenus Inc. Stock Fundamentals & Key Indicators

Check Agenus Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$123.3M

EPS (TTM)

0.5

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

1.44

Industry PE ratio

-3.7464601769911505

PEG Ratio

1.44

EBITDA

15.2M

Revenue (TTM)

123.9M

Profit Margin

52.16%

Return On Equity TTM

-1278.83%

Agenus Inc. Stock Valuation

Track how Agenus Inc. P/E has moved over time to understand its valuation trends.

Agenus Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-68.22x)

June 30, 2021

Industry (-3.75x)

June 19, 2026

Today (1.44x)

June 19, 2026

Highest (6.74x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 1.44x

Agenus Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Agenus Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$123.3M-97.15%1.4452.16%NA
BUY$37.7B57.21%71.2112.55%NA
BUY$116.5B140.42%27.2235.51%NA
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Agenus Inc. Stock including INR - Dollar returns

The Agenus Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Agenus Inc. investment value today

Current value as on today

₹73,106

Returns

-₹26,894

(-26.89%)

Returns from Agenus Inc. Stock

-₹32,886 (-32.89%)

Dollar Impact

₹5,992 (+5.99%)

Analyst Recommendation on Agenus Inc. Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Agenus Inc.. Average target price of $15.5

Agenus Inc. Share Price Target

Get share price movements and forecasts by analysts on Agenus Inc..

What analysts predicted

80.65%UPSIDE

Target Price

$15.5

Current Price

$3

Analyzed by

11 Analysts

Target

$15.50

Agenus Inc. target price $15.5, a slight upside of 80.65% compared to current price of $3. According to 11 analysts rating.

Indian Investors' Interest in Agenus Inc. Stock

Search interest for Agenus Inc. Stock has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-38% versus previous 30 day period

Agenus Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
83
28
23
25
26
24
25
30
34
33
Gross Profit
16
24
-13
-16
-7
2
-1
5
26
33
Operating Income
-4
-32
-30
-31
-25
-13
-16
-4
14
15
EBITDA
0
-30
-19
-28
-22
-10
-13
80
6
54
Interest Expense
44
29
31
35
20
12
13
13
16
14
Depreciation
5
3
3
3
3
3
3
3
0
0
Income Before Tax
-48
-63
-54
-67
-46
-26
-30
63
-10
39
Income Tax Expense
-2
-1
-1
-
-
-
-
-
-
-
Net Income
-46
-61
-53
-66
-45
-25
-27
63
-10
39
Net Profit Margin
-55.24%
-220.98%
-225.79%
-264.36%
-170.88%
-104.99%
-108.81%
211.39%
-30.93%
116.27%

Agenus Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
22
42
36
150
88
295
98
156
103
114
Gross Profit
-72
-73
-87
-18
-56
113
-99
-81
-52
33
Operating Income
-107
-103
-123
-70
-117
25
-179
-159
-120
-20
EBITDA
-104
-95
-130
-63
-114
43
-161
-145
-101
62
Interest Expense
17
18
25
41
61
65
61
97
117
55
Depreciation
-
6
6
6
7
6
6
10
13
9
Income Before Tax
-126
-120
-162
-111
-182
-28
-230
-257
-232
-3
Income Tax Expense
-2
-9
-12
37
57
65
40
-11
-
-
Net Income
-126
-120
-159
-107
-180
-23
-220
-245
-227
0
Net Profit Margin
-562.60%
-281.48%
-434.14%
-71.75%
-205.19%
-8.09%
-224.51%
-157.22%
-219.61%
0.10%

Agenus Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-63
-54
-67
-45
-26
-30
63
-10
39
Operating Cash Flow
-38
-38
-53
-28
-25
-20
-14
-16
-35
Investing Cash Flow
0
0
0
0
0
0
0
0
68
Financing Cash Flow
14
79
4
24
3
10
6
15
0
Change in Cash
-23
40
-48
-4
-21
-8
-7
0
31

Agenus Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-120
-162
-111
-182
-28
-230
-257
-232
-232
Operating Cash Flow
-94
-131
-18
-139
10
-175
-224
-158
-158
Investing Cash Flow
2
-3
-4
-4
-43
-33
3
0
0
Financing Cash Flow
80
128
31
183
225
95
119
122
122
Change in Cash
-11
-7
8
40
192
-113
-101
-35
-35

Global Institutional Holdings in Agenus Inc.

Funds
Holdings
D. E. Shaw & Co LP
0.31%
Morgan Stanley - Brokerage Accounts
0.71%
Vanguard Fiduciary Trust Co
0.48%
Bank of America Corp
0.29%
Goldman Sachs Group Inc
0.49%

Agenus Inc. News & Key Events

  • img

    Today's Timeline - 05 June

    Fri, 11:24 PM

    -

    Agenus prioritizes BOT+BAL for MSS/pMMR mCRC, supported by early survival data and a $91 million collaboration with Zydus Lifesciences.

Insights on Agenus Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -10.57M → 39.22M (in $), with an average increase of 127.0% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Agenus Inc. Common Stock has experienced a drawdown of -92.0%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 70.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 56.9%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 34.20M → 33.73M (in $), with an average decrease of 1.4% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, AGEN stock has moved down by -9.1%

About Agenus Inc.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
OrganisationAgenus Inc.
Headquarters3 Forbes Road, Lexington, MA, United States, 02421-7305
IndustryBiotechnology
CEODr. Garo H. Armen Ph.D.
E-voting on sharesClick here to vote

Key Management of Agenus Inc.

Name

Title

Ms. Tracy Mazza Clemente

Chief People Officer

Dr. Robin G. Taylor M.B.A., Ph.D.

Chief Commercial Officer

Dr. Garo H. Armen Ph.D.

Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman

Dr. Steven J. O'Day M.D., Ph.D.

Chief Medical Officer

Mr. Zack Armen

Vice President of Investor Relations & Corporate Development

Ms. Stefanie Perna-Nacar

Chief Communications & Government Relations Officer

Dr. Todd Jude Yancey M.D.

Member of Advisory Board & Chief Strategic Advisor

Dr. Kamel Djazouli M.D.

Head of Medical Affairs

Dr. Jennifer S. Buell Ph.D.

Director and President & CEO of MiNK Therapeutics

Craig Winter

Chief Information Officer

FAQs

What is Agenus Inc. share price today?

Agenus Inc. share price today is $3 as on at the close of the market. Agenus Inc. share today touched a day high of $3.1 and a low of $2.91.

What is the 52 week high and 52 week low for Agenus Inc. share?

Agenus Inc. share touched a 52 week high of $7.34 on and a 52 week low of $2.71 on . Agenus Inc. stock price today i.e. is closed at $3,which is 59.13% down from its 52 week high and 10.70% up from its 52 week low.

What is Agenus Inc.'s market capitalisation today?

Agenus Inc. market capitalisation is $0.00T as on .

How to invest in Agenus Inc. Stock (AGEN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Agenus Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Agenus Inc. Shares that will get you 0.5000 shares as per Agenus Inc. share price of $3 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Agenus Inc. Stock (AGEN) from India?

Indian investors can start investing in Agenus Inc. (AGEN) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Agenus Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Agenus Inc. share’s latest price of $3 as on June 19, 2026 at 8:46 am IST, you will get 3.3333 shares of Agenus Inc.. Learn more about fractional shares .

What are the returns that Agenus Inc. has given to Indian investors in the last 5 years?

Agenus Inc. stock has given -97.15% share price returns and 27.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?